AIkido Pharma Inc. (AIKI): Price and Financial Metrics

AIkido Pharma Inc. (AIKI)

Today's Latest Price: $1.22 USD

0.02 (-1.61%)

Updated Jan 25 6:55pm

Add AIKI to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

AIKI Stock Summary

  • The ratio of debt to operating expenses for AIkido Pharma Inc is higher than it is for about just 0.5% of US stocks.
  • With a price/sales ratio of 4,733.63, AIkido Pharma Inc has a higher such ratio than 99.68% of stocks in our set.
  • Over the past twelve months, AIKI has reported earnings growth of -3,478.61%, putting it ahead of merely 0.62% of US stocks in our set.
  • Stocks that are quantitatively similar to AIKI, based on their financial statements, market capitalization, and price volatility, are AQB, ATOM, LYL, VTVT, and SPCE.
  • AIKI's SEC filings can be seen here. And to visit AIkido Pharma Inc's official web site, go to

AIKI Stock Price Chart Interactive Chart >

Price chart for AIKI

AIKI Price/Volume Stats

Current price $1.22 52-week high $5.52
Prev. close $1.24 52-week low $0.47
Day low $1.18 Volume 6,251,400
Day high $1.30 Avg. volume 20,389,414
50-day MA $0.76 Dividend yield N/A
200-day MA $0.75 Market Cap 42.60M

AIkido Pharma Inc. (AIKI) Company Bio

Spherix Incorporated, a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The company's platform consists of patented technology from leading universities and researchers and in the process of developing an innovative therapeutic drug platform through partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. It has a scientific research agreement with The University of Texas Southwestern Medical Center to use machine learning to find genetic markers in people that indicate an increased risk of developing pancreatic cancer. Spherix Incorporated was founded in 1967 and is based in New York, New York.

AIKI Latest News Stream

Event/Time News Detail
Loading, please wait...

AIKI Latest Social Stream

Loading social stream, please wait...

View Full AIKI Social Stream

Latest AIKI News From Around the Web

Below are the latest news stories about AIkido Pharma Inc that investors may wish to consider to help them evaluate AIKI as an investment opportunity.

AIkido Pharma regains compliance with NASDAQ

AIkido Pharma ([[AIKI]] +5.0%) has regained compliance with the Nasdaq's $1.00 minimum bid price requirement for continued listing. "We are fully committed to maintaining our Nasdaq listing and value the opportunity to reach a large and diverse community of investors as we continue our efforts to deploy our artificial intelligences...

Seeking Alpha | January 22, 2021

AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements

AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that on January 22, 2021, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market under Listing Rule 5550(a)(2). The Company regained compliance with the NASDAQ's requirements when the closing bid price for the Company's common stock was at or above $1.00 for 10 consecutive business days and the matter is now closed.

Yahoo | January 22, 2021

Silo Pharma Provides Details of Patent License Agreement for Psilocybin and Cancer Applications

Silo Pharma to Receive Upfront Payment Combination of Cash and Preferred Stock Totaling One Million DollarsEnglewood Cliffs, NJ, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, last week announced a licensing agreement with up-front payment valued at $1 Million.  The license agreement (the “Agreement”) with Aikido Pharma Inc., (Nasdaq:AIKI) a listed biotechnology company, grants Akido an exclusive, royalty-bearing license to certain intellectual property owned by Silo Pharma to develop therapeutics for the treatment and complications of cancer.In consideration for granting the license, Silo Pharma received a one-time cash payment of $500,000 and shares of newly designated...

Yahoo | January 11, 2021

AIkido Pharma Inc. Executes Licensing Agreement for Psilocybin for Cancer Applications

AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company executed a Patent License Agreement for technology that covers the use of psilocybin for cancer applications. The technology is covered by four patent applications already on file with the United States Patent and Trademark Office.

Yahoo | January 6, 2021

AIkido Pharma Inc. Announces Publication of Favorable Peer Reviewed Study of Newly Licensed Antiviral Compounds

AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced the publication of positive results from a study of antiviral activity of FDA approved drugs in a peer-reviewed article in the Proceedings of the National Academy of Sciences of the United States of America (PNAS). The publication reports studies on newly discovered antiviral compounds that were developed using a computer modeling approach. The lead compounds were found to have broad-spectrum antiviral activity, inhibiting influenza virus, Ebola, Marburg, MERS-CoV, SARS-CoV, and SARS-CoV2, the virus that causes COVID-19.

Yahoo | November 13, 2020

Read More 'AIKI' Stories Here

AIKI Price Returns

1-mo N/A
3-mo 110.34%
6-mo 6.09%
1-year 0.83%
3-year -79.78%
5-year -87.41%
YTD 39.67%
2020 -33.83%
2019 -51.47%
2018 -54.29%
2017 34.62%
2016 -63.51%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7467 seconds.